Kidney Neoplasm Clinical Trial
Official title:
SPECT/CT for the Characterization of Renal Masses: Impact on Clinical Decision Making
This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check for kidney tumors.
PRIMARY OBJECTIVES: I. To determine the impact of technetium Tc-99m sestamibi (MIBI) SPECT/CT on patient management decisions. SECONDARY OBJECTIVES: I. To evaluate the impact of MIBI SPECT/CT on patient management decisions for tumors 1.5-3.0 cm and 3.1-5.0 cm. II. To assess the impact of MIBI SPECT/CT on decisional conflict score. III. To assess the impact of MIBI SPECT/CT on physician management recommendation. IV. To evaluate the sensitivity and specificity of MIBI SPECT/CT for the identification of an oncocytic renal mass (oncocytoma, chromophobe, and hybrid oncocytic tumor) with respect to tumor histology identified by renal mass biopsy or surgical resection. V. To compare the specificity of MIBI SPECT/CT with conventional cross-sectional imaging in predicting an oncocytic renal mass. VI. To assess the correlation between MIBI SPECT/CT outcomes to final treatment decisions. EXPLORATORY OBJECTIVES: I. Evaluate the mitochondria content in tumors that had positive MIBI SPECT/CT findings. OUTLINE: Patients receive technetium Tc-99m sestamibi intravenously (IV) then undergo SPECT/CT. After completion of study, patients are followed up for 6 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01961583 -
[18F]Fluciclatide PET Imaging of Pazopanib Response
|
Phase 2 | |
| Completed |
NCT00001302 -
A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833
|
Phase 1 | |
| Completed |
NCT01896778 -
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
|
N/A | |
| Enrolling by invitation |
NCT02287987 -
CLamp vs Off Clamp Kidney During Partial Nephrectomy
|
N/A | |
| Recruiting |
NCT04644432 -
Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT05817604 -
Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)
|
||
| Completed |
NCT00888641 -
A Pilot Study of Renal Hypothermia During Partial Nephrectomy
|
Phase 1 | |
| Completed |
NCT00199875 -
Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
|
Phase 1 | |
| Recruiting |
NCT00994188 -
A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Family Members
|
N/A | |
| Recruiting |
NCT02346435 -
The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
|
||
| Completed |
NCT01087060 -
Detection of Renal Malignancy of Complicated Renal Cysts
|
N/A | |
| Recruiting |
NCT04258462 -
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
|
Phase 2 | |
| Recruiting |
NCT00898365 -
Study of Kidney Tumors in Younger Patients
|
||
| Recruiting |
NCT04823923 -
Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer
|
N/A | |
| Not yet recruiting |
NCT04681690 -
German National Registry for NSS
|
||
| Not yet recruiting |
NCT05135832 -
Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma
|
N/A | |
| Recruiting |
NCT04602702 -
Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors
|
||
| Terminated |
NCT00005655 -
Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT05887245 -
Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy
|